AU2001294007A1 - Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers - Google Patents

Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers

Info

Publication number
AU2001294007A1
AU2001294007A1 AU2001294007A AU9400701A AU2001294007A1 AU 2001294007 A1 AU2001294007 A1 AU 2001294007A1 AU 2001294007 A AU2001294007 A AU 2001294007A AU 9400701 A AU9400701 A AU 9400701A AU 2001294007 A1 AU2001294007 A1 AU 2001294007A1
Authority
AU
Australia
Prior art keywords
oxapenem
lyophilisation
carboxylic acids
pharmaceutical carriers
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294007A
Inventor
Hans Rudolf Pfaendler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amura Ltd
Original Assignee
Amura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amura Ltd filed Critical Amura Ltd
Publication of AU2001294007A1 publication Critical patent/AU2001294007A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

According to the present invention there is provided a pharmaceutical composition comprising a co-lyophilizate of: a pharmaceutical carrier; and an active ingredient of formulae I and II or a pharmaceutically acceptable salt thereof, <CHEM> wherein R<1> and R<2>, independently of one another, denote hydrogen, or pharmaceutically acceptable groups which have 1 to 10 carbon atoms and are bonded to the remaining part of the molecule via carbon-carbon single bonds and in which R<3>, R<4> and R<5>, independently of one another, denote pharmaceutically acceptable groups which are bonded to the exocyclic, allylic carbon atom via carbon atoms.
AU2001294007A 2000-10-19 2001-10-11 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers Abandoned AU2001294007A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00309207 2000-10-19
EP00309207A EP1199077A1 (en) 2000-10-19 2000-10-19 Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers
PCT/GB2001/004530 WO2002032424A1 (en) 2000-10-19 2001-10-11 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers

Publications (1)

Publication Number Publication Date
AU2001294007A1 true AU2001294007A1 (en) 2002-04-29

Family

ID=8173326

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294007A Abandoned AU2001294007A1 (en) 2000-10-19 2001-10-11 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers

Country Status (12)

Country Link
US (1) US20040043980A1 (en)
EP (2) EP1199077A1 (en)
JP (1) JP2004511520A (en)
AT (1) ATE311881T1 (en)
AU (1) AU2001294007A1 (en)
CY (1) CY1106058T1 (en)
DE (1) DE60115687T2 (en)
DK (1) DK1326608T3 (en)
ES (1) ES2250483T3 (en)
HK (1) HK1053612A1 (en)
WO (1) WO2002032424A1 (en)
ZA (1) ZA200302804B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003280A (en) * 2000-10-19 2004-12-13 Amura Ltd Pharmaceutical compositions containing oxapenem-3-carboxylic acids.
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition
AR039774A1 (en) * 2002-05-01 2005-03-02 Wyeth Corp 6-BICYCLE RENTAL-PENEMS AS BETA-LACTAMASAS INHIBITORS
AR039475A1 (en) * 2002-05-01 2005-02-23 Wyeth Corp 6-ALQUILIDEN-PENEMS TRICICLICOS AS BETA-LACTAMASA INHIBITORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US43980A (en) * 1864-08-30 Improvement in horse-rakes
US176349A (en) * 1876-04-18 Improvement in carbureters
GB2045236A (en) * 1979-03-26 1980-10-29 Hoechst Uk Ltd Oxapenem derivatives
US4293555A (en) * 1979-04-17 1981-10-06 Merck & Co., Inc. 6- and 6,6-Disubstituted-2-substituted-oxapen-2-em-3-carboxylic acids
DE2925009A1 (en) * 1979-06-21 1981-01-08 Basf Ag PREPARATION FOR SUBSTANCES, METHOD FOR THE PRODUCTION AND USE THEREOF
DE3725375A1 (en) * 1987-07-31 1989-02-09 Bayer Ag STABLE OXAPENEM-3-CARBONSAEURES
DE3833693A1 (en) * 1988-10-04 1990-04-05 Bayer Ag STABLE OXAPENEM-3-CARBONSAEURES AND THEIR USE AS SS-LACTAMATE HEMMER
DE4027928A1 (en) * 1990-09-04 1992-03-05 Bayer Ag NEW 2-TERT.SUBSTITUTED METHYL-OXAPENEM-3-CARBONIC ACIDS AND ESTERS, PROCESS FOR THEIR PRODUCTION AND THEIR USE
DE4142423A1 (en) * 1991-12-20 1993-06-24 Pfaendler Hans Rudolf ((LS) -HYDROXYALKYL) OXAPENEM-3-CARBON ACIDS AND THEIR USE AS BETALACTAMATE HEMMER
NZ285085A (en) * 1994-04-25 1998-04-27 Smithkline Beecham Plc Penem composition, pharmaceutical formulation containing a beta-lactamase inhibiting penem and a beta-lactam antibiotic
WO1996038450A1 (en) * 1995-05-31 1996-12-05 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics

Also Published As

Publication number Publication date
ZA200302804B (en) 2005-02-23
EP1326608A1 (en) 2003-07-16
DE60115687T2 (en) 2006-06-29
JP2004511520A (en) 2004-04-15
ATE311881T1 (en) 2005-12-15
DE60115687D1 (en) 2006-01-12
US20040043980A1 (en) 2004-03-04
DK1326608T3 (en) 2006-02-06
CY1106058T1 (en) 2011-04-06
ES2250483T3 (en) 2006-04-16
WO2002032424A1 (en) 2002-04-25
HK1053612A1 (en) 2003-10-31
EP1326608B1 (en) 2005-12-07
EP1199077A1 (en) 2002-04-24

Similar Documents

Publication Publication Date Title
AU6801090A (en) Peptide compounds, a process for preparation thereof and pharmaceutical composition comprising the same
GB0019231D0 (en) Antiperspirant compositions
FI964920A (en) New farnesyl transferase inhibitors, their preparation and those containing pharmaceutical preparations
AUPR213700A0 (en) Antiviral agents
HUP0004040A1 (en) Pleuromutilin derivatives as antimicrobials, process for their preparation, pharmaceutical compositions, comprising thereof and their use
GEP20053541B (en) Pyrrolo[2,3-d]Pyrimidine Compounds
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
EP1193256A8 (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
PT992509E (en) NEW MACROLIDED DERIVATIVES
IL114785A0 (en) Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them
AU3707197A (en) Active oxygen scavengers containing pterin derivatives
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
WO2002007677A3 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
FI891581A0 (en) PEPTIDDERIVAT.
AU2001294007A1 (en) Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
FR2771412B1 (en) NOVEL PYRROLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1147330B (en) CYSTOSTATIC ACTION, OR PHARMACEUTICAL PREPARATION
IL89538A0 (en) Peptides,their preparation and pharmaceutical compositions containing them
EP1390343A4 (en) Novel retinoid derivatives and methods for producing said compounds and an anti-cancer pharmaceutical composition comprising said compounds
SE9701912D0 (en) Pharmaceutical composition and use thereof
EP1227098A4 (en) Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents
MXPA99003849A (en) 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin.
AU2224795A (en) Ameliorant or remedy for paraneoplastic syndrome
IL89537A0 (en) Peptides,their preparation and pharmaceutical compositions containing them